• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

    6/12/24 8:00:00 AM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLRX alert in real time by email

    HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-8 reverse stock split at 5:00 p.m. Eastern Time, on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Salarius' common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X404 and the Company's existing trading symbol "SLRX."

    The reverse stock split is intended to enable Salarius to regain compliance with the $1.00 minimum closing bid price required for continued listing on the Nasdaq Capital Market.

    At a special meeting of stockholders held on May 9, 2024, Salarius' stockholders approved the proposal to authorize Salarius' Board of Directors to file an amendment to Salarius' amended and restated certificate of incorporation ("Certificate of Incorporation") to effect the reverse split at a ratio to be determined by the Board, ranging from 1-for-4 to 1-for-8. The specific 1-for-8 ratio was subsequently approved by Salarius' Board of Directors and the reverse stock split will be effected by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware. No further action is required by any stockholders in connection with approving or effecting the reverse stock split.

    The reverse split will affect all issued and outstanding shares of Salarius' common stock. At the effective time of the reverse stock split, the number of shares of common stock issued and outstanding will be reduced from approximately 4.7 million shares to approximately 0.6 million shares. All outstanding options and warrants entitling their holders to purchase shares of Salarius' common stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares reserved for future issuance pursuant to Salarius' 2015 Equity Incentive Plan and the number of shares reserved for future issuance pursuant to Salarius' 2015 Employee Stock Purchase Plan also will be appropriately adjusted. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of Salarius' shares (except to the extent that the reverse stock split would result in some of the stockholders receiving cash in lieu of fractional shares). Stockholders will receive cash in lieu of fractional shares based on the closing price per share of Salarius' common stock as quoted on the Nasdaq Capital Market on June 14, 2024. The reverse stock split will not reduce the number of authorized shares of common stock or preferred stock or change the par values of Salarius' common stock (which will remain at $0.0001 per share) or preferred stock (which will remain at $0.0001 per share).

    Equiniti Trust Company, LLC, ("Equiniti") is acting as the exchange agent and transfer agent for the reverse stock split. Equiniti will provide instructions to stockholders with physical certificates regarding the process for exchanging their pre-split stock certificates for post-split shares in book-entry form and receiving payment for any fractional shares.

    Additional information about the reverse stock split can be found in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission ("SEC") on March 26, 2024. The Proxy Statement is available at www.sec.gov or at Salarius' website at salariuspharma.com here.

    About Salarius Pharmaceuticals

    Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. Salarius' product portfolio includes seclidemstat, its lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of non-Hodgkin's lymphoma. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma program and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.

    Safe Harbor Statement

    This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the reverse split and the timing thereof and expectations related thereto; and other statements that are not historical fact.

    The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Some factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

    CONTACT:

    LHA Investor Relations

    Kim Sutton Golodetz

    [email protected]

    212-838-3777



    Primary Logo

    Get the next $SLRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SLRX

    DatePrice TargetRatingAnalyst
    3/11/2022$5.00 → $4.00Buy
    HC Wainwright & Co.
    8/25/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Salarius Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $5.00 previously

      3/11/22 6:32:47 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Salarius Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $5.00

      8/25/21 6:10:11 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Arthur David J.

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      4/12/24 4:50:27 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Rosenblum Mark J

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      2/22/24 4:37:10 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mcvicar William K.

      4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

      2/22/24 4:29:33 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

      CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t

      4/16/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

      CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide-conjugate therapeutics, announced that a series of antiviral drug candidates previously designed by its IMP3ACT™ platform to be broadly effective against viruses of the paramyxoviridae family also showed promising in silico activity against measles and Nipah viruses. As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) signed a definitive merger agreement pursuant to which Decoy will merge with a wholly owned subsidiary of Salarius, subject to satisfaction of th

      3/26/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

      Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer Updates expected later this year from the MD Anderson Cancer Center (MDACC) investigator-initiated Phase 1/2 clinical trial of seclidemstat in combination with azacitidine to treat hematologic cancers HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today repor

      3/24/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by Salarius Pharmaceuticals Inc.

      S-1/A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      6/16/25 5:01:52 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      6/16/25 4:06:22 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

      6/11/25 8:38:51 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

      CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t

      4/16/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

      HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has been named Director of the Company's new targeted protein degradation program. In this newly created position, Dr. Santiesteban will assume responsibility for overseeing the development of SP-3164, the program's lead drug candidate, and advancing it into clinical trials. Her appointment immediately follows Salarius' recent strategic expansion into the targeted protein degradation field through its acquisitio

      2/3/22 7:30:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Financials

    Live finance-specific insights

    See more
    • Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH

      HOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, will hold a conference call with slides to discuss recent clinical and preclinical data from its lead programs on December 14, 2022 at 11:00 a.m. Eastern time. Management will review recently announced interim results from its ongoing Phase 1/2 trial with seclidemstat in Ewing sarcoma and FET-rearranged sarcomas, as well as new clinical data from MD Anderson Cancer Center's study with seclidemstat plus azacytidine in hematological cancer

      12/8/22 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

      60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who Achieved Confirmed Disease Control HOUSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company's Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment fo

      12/1/22 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

      HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the quarter and recent weeks included: Financial Highlights Cash and equivalents were $22.6 million as of June 30, 2022, compared with $29.2 million as of December 31, 2021Tightly managed expenses while progressing toward multiple near-term milestonesNet loss of $4.7 million, or $0.09 per share, compared with net loss of $3.1 million, or $0.07 per share,

      8/8/22 8:30:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc.

      SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      11/14/24 4:38:31 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Salarius Pharmaceuticals Inc.

      SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      2/14/24 3:54:30 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

      2/13/23 4:30:18 PM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care